These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. VEGF and podocytes in diabetic nephropathy. Tufro A; Veron D Semin Nephrol; 2012 Jul; 32(4):385-93. PubMed ID: 22958493 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395 [TBL] [Abstract][Full Text] [Related]
8. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Wolf G; Chen S; Ziyadeh FN Diabetes; 2005 Jun; 54(6):1626-34. PubMed ID: 15919782 [TBL] [Abstract][Full Text] [Related]
9. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Advani A; Wiggins KJ; Cox AJ; Zhang Y; Gilbert RE; Kelly DJ Nephrology (Carlton); 2011 Aug; 16(6):573-81. PubMed ID: 21342330 [TBL] [Abstract][Full Text] [Related]
11. AMPK signalling: Implications for podocyte biology in diabetic nephropathy. Szrejder M; Piwkowska A Biol Cell; 2019 May; 111(5):109-120. PubMed ID: 30702162 [TBL] [Abstract][Full Text] [Related]
13. A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism. Nakagawa T Clin Nephrol; 2009 Feb; 71(2):103-9. PubMed ID: 19203501 [TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932 [TBL] [Abstract][Full Text] [Related]
16. Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease. Sun PP; Yu XJ; Wang SX; Zhou XJ; Qu L; Zhang F; Ma YY; Liu G; Yang L Nephrology (Carlton); 2020 Feb; 25(2):125-134. PubMed ID: 31264312 [TBL] [Abstract][Full Text] [Related]
17. The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes. Bus P; Scharpfenecker M; Van Der Wilk P; Wolterbeek R; Bruijn JA; Baelde HJ Diabetologia; 2017 Sep; 60(9):1813-1821. PubMed ID: 28620823 [TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390 [TBL] [Abstract][Full Text] [Related]
19. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Ku CH; White KE; Dei Cas A; Hayward A; Webster Z; Bilous R; Marshall S; Viberti G; Gnudi L Diabetes; 2008 Oct; 57(10):2824-33. PubMed ID: 18647955 [TBL] [Abstract][Full Text] [Related]
20. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]